Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 27Breast 26Genitourinary 18Gastrointestinal 11Thoracic 8Sarcoma 5CNS 5Head & Neck 4Tumor-Agnostic 2Other solid neoplasm 2Myeloid 2Other hematologic neoplasm 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Fanconi Anemia, Complementation Group D1 1Breast Neoplasms 1

Interventions

Cyclophosphamide 8Whole-Body Irradiation 6fludarabine 5fludarabine phosphate 4Tacrolimus 4Mycophenolic Acid 4Melphalan 4Busulfan 3luspatercept 2Vorinostat 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Biopsy 2Azacitidine 2AP 1903 reagent 2venetoclax 1ribociclib 1palbociclib 1olaparib 1ibrutinib 1hetrombopag 1edoxaban 1decitabine and cedazuridine drug combination 1apixaban 1acalabrutinib 1abemaciclib 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × olaparib × Classical hematology × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡